ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2017
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.Journal of neurology · 2022Pooled it
- Impact of an electronic monitoring device and behavioral feedback on adherence to multiple sclerosis therapies in youth: results of a randomized trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Trial
- Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.Neurology and therapy · 2026Article
- Personality Traits and Their Association With Medication Non-Adherence in Patients With Multiple Sclerosis.CNS neuroscience & therapeutics · 2026Article
- Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment.Hospital pharmacy · 2024Article
- Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.Turkish journal of medical sciences · 2023Article
- Etiology, effects and management of comorbidities in multiple sclerosis: recent advances.Frontiers in immunology · 2023Review
- Switching to second line MS disease-modifying therapies is associated with decreased relapse rate.Frontiers in neurology · 2023Article
- Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain.Patient preference and adherence · 2023Article
- The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis-Cross-Sectional Study.International journal of environmental research and public health · 2022Article
- Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study.Scientific reports · 2022Article
- Medication Adherence and Belief about Medication among Vietnamese Patients with Chronic Cardiovascular Diseases within the Context of Implementing Measures to Prevent COVID-19.Journal of cardiovascular development and disease · 2022Article
- Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.Journal of neurology · 2022Article
- Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse.Annals of neurology · 2022Article
- Adherence to Therapy in Patients with Multiple Sclerosis-Review.International journal of environmental research and public health · 2022Review
- Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.Patient preference and adherence · 2022Review
- The Impact of Motor Disability and the Level of Fatigue on Adherence to Therapeutic Recommendations in Patients with Multiple Sclerosis Treated with Immunomodulation.International journal of medical sciences · 2021Article
- The Levels of Depression, Anxiety, Acceptance of Illness, and Medication Adherence in Patients with Multiple Sclerosis - Descriptive and Correlational Study.International journal of medical sciences · 2021Observational
- Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.BMC neurology · 2020Article
- Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.Journal of neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoor adherence to the disease-modifying therapies (DMTs) for multiple sclerosis (MS) may attenuate clinical benefit. A better understanding of characteristics associated with non-adherence could improve outcomes.
objectiveTo evaluate characteristics associated with non-adherence to injectable DMTs.
methodsConsecutive patients from four Canadian MS Clinics were assessed at three time points over two years. Clinical and demographic information included self-reported DMT use, missed doses in the previous 30 days, health behaviors, and comorbidities. Non-adherence was defined as <80% of expected doses taken. We employed generalized estimating equations to examine characteristics associated with non-adherence at all time points with findings reported as adjusted odds ratios (OR).
resultsIn all, 485 participants reported use of an injectable DMT, of whom 107 (22.1%) were non-adherent over the study period. Non-adherence was associated with a lower Expanded Disability Status Scale score (0-2.5 vs 3.0-5.5, OR: 1.80; 95% confidence interval (CI): 1.06-3.04), disease duration (⩽5 vs <5 years, OR: 2.23; 95% CI: 1.10-4.52), alcohol dependence (OR: 2.14; 95% CI: 1.23-3.75), and self-reported cognitive difficulties, measured by the Health Utilities Index-3 (OR: 1.55; 95% CI: 1.08-2.22).
conclusionsNearly one-quarter of participants were non-adherent during the study. Alcohol dependence, perceived cognitive difficulties, longer disease duration, and mild disability status were associated with non-adherence. These characteristics may help healthcare professionals identify patients at greatest risk of poor adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.